Advertisement


Michael J. Overman, MD, and François Quenet, MD, on Colorectal Cancer: Results From the PRODIGE 7 Trial

2018 ASCO Annual Meeting

Advertisement

Michael J. Overman, MD, of The University of Texas MD Anderson Cancer Center, and François Quenet, MD, of the Institut Régional du Cancer de Montpellier, discuss phase III study findings on hyperthermic intraperitoneal chemotherapy for colorectal peritoneal carcinomatosis (Abstract LBA3503).



Related Videos

Lung Cancer

Geoffrey R. Oxnard, MD, on Lung Cancer: Results From the Circulating Cancer Genome Atlas Study

Geoffrey R. Oxnard, MD, of Dana-Farber Cancer Institute, discusses genome-wide sequencing for early-stage lung cancer detection from plasma cell–free DNA (Abstract LBA8501).

Multiple Myeloma

Aviva C. Krauss, MD, on Multiple Myeloma: Treatment Trials Analysis

Aviva C. Krauss, MD, of the U.S. Food and Drug Administration, discusses findings on an FDA analysis of immune-related adverse events and response to pembrolizumab in multiple myeloma (Abstract 8008).

Geriatric Oncology

Supriya G. Mohile, MD, on Communicating With Older Cancer Patients: Results From a Community Trial

Supriya G. Mohile, MD, of the University of Rochester Medical Center, discusses study findings on ways to improve communication with older cancer patients using geriatric assessment (Abstract LBA10003).

Prostate Cancer

Susan Halabi, PhD, on Prostate Cancer: Overall Survival for Black vs White Men

Susan Halabi, PhD, of Duke University Medical Center, discusses an analysis that showed an increase in overall survival in African American men vs Caucasian men, all of whom had metastatic castration-resistant prostate cancer treated with docetaxel/prednisone or a regimen containing those agents (Abstract LBA5005).

Gynecologic Cancers

Ursula A. Matulonis, MD, and Daniel J. Margul, MD, PhD, on Cervical Cancer and Minimally Invasive Surgery

Ursula A. Matulonis, MD, of Dana-Farber Cancer Institute, and Daniel J. Margul, MD, PhD, of Northwestern University, discuss the outcomes and costs of open, robotic, and laparoscopic radical hysterectomy for stage IB1 cervical cancer (Abstract 5502).

Advertisement

Advertisement




Advertisement